Usefulness of quantitative cytomegalovirus antigenemia determinations in heart transplantation.
Manito
N
N
Servicio de Cardiología, Ciudad Sanitaria y Universitaria de Bellvitge, Barcelona, Spain.
Perez
J L
JL
Roca
J
J
Castells
E
E
Niubó
J
J
Garcia
A
A
Ribas
M
M
Saura
E
E
Rufí
G
G
Gomez-Hospital
J A
JA
Espinoza
C
C
Esplugas
E
E
D000956:Antigens, Viral / Q000097:blood*; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000097:blood / Q000175:diagnosis*; D004359:Drug Therapy, Combination; D019084:Fluorescent Antibody Technique, Indirect; D016027:Heart Transplantation / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011183:Postoperative Complications / Q000175:diagnosis; D011241:Prednisone / Q000627:therapeutic use; D011446:Prospective Studies
D000956:Antigens, Viral; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D009173:Mycophenolic Acid; D001379:Azathioprine; D011241:Prednisone